ResearcherAzienda Ospedaliera Citta' della Salute e della Scienza di TorinoActive in the last 2 years
Silvia Brugiapaglia
Matched on ORCID iD 0000-0002-8159-0449; OpenAlex author ID A5025545281. Sources: OpenAlex.
Their work
- Papers
- 9 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 25
2020: 1 paper · 2021: 1 paper · 2022: none · 2023: 2 papers · 2024: 3 papers · 2025: 2 papers
Papers 9
- The absence of IL17A favours cytotoxic cell function and improves antigen-specific immunotherapies in pancreatic adenocarcinoma. Co-author DOI 10.1002/ctm2.70442↗
- Unlocking the Potential of Bioactive Compounds in Pancreatic Cancer Therapy: A Promising Frontier. Co-author DOI 10.3390/biom15050725↗
- PI3Kγ inhibition combined with DNA vaccination unleashes a B-cell-dependent antitumor immunity that hampers pancreatic cancer. Co-author DOI 10.1186/s13046-024-03080-1↗
- In pancreatic cancer patients, chemotherapy reshapes the gene expression profile and antigen receptor repertoire of T lymphocytes and enhances their effector r… Co-author DOI 10.3389/fimmu.2024.1427424↗
- Fighting Pancreatic Cancer with a Vaccine-Based Winning Combination: Hope or Reality? Co-author DOI 10.3390/cells13181558↗
- Circulating autoantibodies to alpha-enolase (ENO1) and far upstream element-binding protein 1 (FUBP1) are negative prognostic factors for pancreatic cancer pat… Co-author DOI 10.1007/s10238-023-01236-5↗
- IL-1β+ macrophages fuel pathogenic inflammation in pancreatic cancer. Co-author DOI 10.1038/s41586-023-06685-2↗
- The Glycolytic Pathway as a Target for Novel Onco-Immunology Therapies in Pancreatic Cancer. First author DOI 10.3390/molecules26061642↗
- The dark side of immunotherapy: pancreatic cancer. Co-author DOI 10.20517/cdr.2020.13↗
Closest collaborators
The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Claudia Curcio · 7 shared papers, 2021–2025 · strength 1.57
- Paper Unlocking the Potential of Bioactive Compounds in Pancreatic Cancer Therapy: A Promising Frontier. DOI 10.3390/biom15050725↗
- Paper Fighting Pancreatic Cancer with a Vaccine-Based Winning Combination: Hope or Reality? DOI 10.3390/cells13181558↗
- Paper The absence of IL17A favours cytotoxic cell function and improves antigen-specific immunotherapies in pancreatic adenoc… DOI 10.1002/ctm2.70442↗
- Francesco Novelli · 8 shared papers, 2020–2025 · strength 1.39
- Paper Fighting Pancreatic Cancer with a Vaccine-Based Winning Combination: Hope or Reality? DOI 10.3390/cells13181558↗
- Paper The absence of IL17A favours cytotoxic cell function and improves antigen-specific immunotherapies in pancreatic adenoc… DOI 10.1002/ctm2.70442↗
- Paper PI3Kγ inhibition combined with DNA vaccination unleashes a B-cell-dependent antitumor immunity that hampers pancreatic … DOI 10.1186/s13046-024-03080-1↗
- Paola Cappello · 6 shared papers, 2020–2025 · strength 0.98
- Paper The absence of IL17A favours cytotoxic cell function and improves antigen-specific immunotherapies in pancreatic adenoc… DOI 10.1002/ctm2.70442↗
- Paper PI3Kγ inhibition combined with DNA vaccination unleashes a B-cell-dependent antitumor immunity that hampers pancreatic … DOI 10.1186/s13046-024-03080-1↗
- Paper In pancreatic cancer patients, chemotherapy reshapes the gene expression profile and antigen receptor repertoire of T l… DOI 10.3389/fimmu.2024.1427424↗
- Cecilia Roux · 3 shared papers, 2020–2025 · strength 0.52
- Paper The absence of IL17A favours cytotoxic cell function and improves antigen-specific immunotherapies in pancreatic adenoc… DOI 10.1002/ctm2.70442↗
- Paper PI3Kγ inhibition combined with DNA vaccination unleashes a B-cell-dependent antitumor immunity that hampers pancreatic … DOI 10.1186/s13046-024-03080-1↗
- Paper The dark side of immunotherapy: pancreatic cancer. DOI 10.20517/cdr.2020.13↗
- Gianluca Mucciolo · 3 shared papers, 2020–2025 · strength 0.52
- Paper The absence of IL17A favours cytotoxic cell function and improves antigen-specific immunotherapies in pancreatic adenoc… DOI 10.1002/ctm2.70442↗
- Paper PI3Kγ inhibition combined with DNA vaccination unleashes a B-cell-dependent antitumor immunity that hampers pancreatic … DOI 10.1186/s13046-024-03080-1↗
- Paper The dark side of immunotherapy: pancreatic cancer. DOI 10.20517/cdr.2020.13↗
- Rosella Spadi · 2 shared papers, 2023–2024 · strength 0.32
- Paper In pancreatic cancer patients, chemotherapy reshapes the gene expression profile and antigen receptor repertoire of T l… DOI 10.3389/fimmu.2024.1427424↗
- Paper Circulating autoantibodies to alpha-enolase (ENO1) and far upstream element-binding protein 1 (FUBP1) are negative prog… DOI 10.1007/s10238-023-01236-5↗
- Giorgia Tiberi · 1 shared paper, 2025 · strength 0.20
- Giulia Adriani · 1 shared paper, 2025 · strength 0.20
- Francesca Cordero · 1 shared paper, 2024 · strength 0.18
- Judith A. Varner · 1 shared paper, 2024 · strength 0.18
- Laura Follia · 1 shared paper, 2021 · strength 0.16
- Claudio De Angelis · 1 shared paper, 2023 · strength 0.14
- Elisabetta Fenocchio · 1 shared paper, 2023 · strength 0.14
- Alessandro Ferrero · 1 shared paper, 2023 · strength 0.14
- Serena Langella · 1 shared paper, 2023 · strength 0.14
- Florent Ginhoux · 1 shared paper, 2023 · strength 0.11
- Nicoletta Caronni · 1 shared paper, 2023 · strength 0.11
- Claudio Doglioni · 1 shared paper, 2023 · strength 0.11
- Vincenzo Corbo · 1 shared paper, 2023 · strength 0.11
- Erica Dugnani · 1 shared paper, 2023 · strength 0.11
- Renato Ostuni · 1 shared paper, 2023 · strength 0.11
- Massimo Falconi · 1 shared paper, 2023 · strength 0.11
- Marco Schiavo Lena · 1 shared paper, 2023 · strength 0.11
- Lorenzo Piemonti · 1 shared paper, 2023 · strength 0.11
- Stefano Crippa · 1 shared paper, 2023 · strength 0.11
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.